What is WO2011013785 (delgocitinib) and what does it cover?
WO2011013785 is a patent application published under the PCT system that relates to delgocitinib, an inhibitor developed in the Janus kinase (JAK) space. The application is identified as “delgocitinib” within the publication record and is used as a source for legal and technical claims around the drug and related subject matter (as defined in the patent text itself).
Because the underlying claim set can span multiple categories (for example, composition, methods of treatment, and/or specific compound forms), the exact coverage depends on the claims in the published document, not just the drug name in the title/record.
When does the WO2011013785 delgocitinib patent expire?
WO publications themselves usually do not map 1:1 to a single “expiry date” because a WO application typically enters national/regional phases in specific countries, and term can vary by jurisdiction and filing date. In practice, the expiry timing is driven by:
- the earliest priority date claimed in the application, and
- the patent term rules in each country where it was granted or became effective.
To determine the expiry date for “WO2011013785 delgocitinib” in a specific country, you need the application’s earliest priority date and the national grant(s) that came out of it.
Was WO2011013785 granted as patents in specific countries?
A WO publication can later lead to one or more granted patents in countries (or rejections), depending on national examination and local decisions. So the key questions for users searching this WO number are:
- which jurisdictions granted patents based on WO2011013785, and
- what the grant numbers and claim scopes were in those jurisdictions.
That requires looking up the national phase outcomes for this specific WO filing.
Who owns WO2011013785 and who are the competitors?
Ownership and assignees vary by filing stage and by how the rights were transferred. Competitors become relevant because delgocitinib-related families often overlap with other JAK inhibitor programs, and different companies may hold adjacent or overlapping claims.
To answer “who owns it” accurately, you must check the assignee/applicant and any continuation/divisional family documents tied to this WO record.
How to check infringement risk for delgocitinib based on WO2011013785?
Infringement and freedom-to-operate analyses depend on:
- the exact independent claims and their dependent claim coverage,
- the jurisdiction’s claim construction approach,
- whether the product/process falls within claim elements (drug structure, formulation, dosing, patient selection, endpoints, etc.), and
- whether later amendments, re-examination, or invalidation occurred.
A common practical workflow is to:
1) pull the claims from WO2011013785,
2) identify the granted/jurisdictional equivalents, and
3) compare them element-by-element against the specific delgocitinib product and clinical use.
What to do if you’re trying to validate this WO number for a legal filing?
If you need this for a clearance or litigation docket, verify:
- the publication date and WO application number formatting,
- the earliest priority date used for term calculations,
- the assignee/applicant,
- whether there are multiple family members (continuations/divisionals) with different priority dates,
- and which jurisdictions actually granted.
Sources
I don’t have access to the patent text or external patent databases from your prompt alone, so I can’t reliably state the claims, assignee, priority date, grant status, or expiry date for WO2011013785 here.
If you share either (a) the link to the record (e.g., WIPO Patentscope/Espacenet) or (b) the earliest priority date and the main assignee/grant countries you care about, I can narrow this to the specific expiry timeline and what the claims cover.